Japan, Sept. 24 -- Lantheus Holdings, Inc. and GE HealthCare announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus' piflufolastat F18 (PYLARIFY(R) in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development in Japan, towards potential regulatory submissions and commercial launch. GE HealthCare will draw on its extensive manufacturing network and...